Acquired TIGIT expression in TCs with mantle cell lymphoma relapse enhances the interaction of TIGIT+ TCs with monocyte CD155/PVR 44, suggesting that a rational strategy could be considered for targeting TIGIT to enhance the anti-tumor immunotherapy efficacy. The gene discussed is PVR; the disease is neoplasm.